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ABSTRACT: Regulatory RNA-based interactions are critical for
coordinating gene expression and are increasingly being targeted in
synthetic biology, antimicrobial, and therapeutic fields. Bacterial
trans-encoded small RNAs (sRNAs) regulate the translation and/
or stability of mRNA targets through base-pairing interactions.
These interactions are often integral to complex gene circuits
which coordinate critical bacterial processes. The ability to
predictably modulate these gene circuits has potential for
reprogramming gene expression for synthetic biology and
antibacterial purposes. Here, we present a novel pipeline for
targeting such RNA-based interactions with antisense oligonucleo-
tides (ASOs) in order to reprogram gene expression. As proof-of-concept, we selected sRNA−mRNA interactions that are central to
the Vibrio cholerae quorum sensing pathway, required for V. cholerae pathogenesis, as a regulatory RNA-based interaction input. We
rationally designed anti-sRNA ASOs to target the sRNAs and synthesized them as peptide nucleic acids (PNAs). Next, we devised an
RNA array-based interaction assay to allow screening of the anti-sRNA ASOs in vitro. Finally, an Escherichia coli-based gene
expression reporter assay was developed and used to validate anti-sRNA ASO regulatory activity in a cellular environment. The
output from the pipeline was an anti-sRNA ASO that targets sRNAs to inhibit sRNA−mRNA interactions and modulate gene
expression. This anti-sRNA ASO has potential for reprogramming gene expression for synthetic biology and/or antibacterial
purposes. We anticipate that this pipeline will find widespread use in fields targeting RNA-based interactions as modulators of gene
expression.
KEYWORDS: antisense oligonucleotide (ASO), peptide nucleic acid (PNA), reprogramming gene expression, RNA array,
RNA−RNA interactions, small regulatory RNA (sRNA)
■ INTRODUCTION
RNA-based interactions, between noncoding RNAs and
proteins, RNAs, and/or DNA, are essential for coordinating
gene expression.1 These regulatory interactions are increasingly
being targeted in antimicrobial, therapeutic, and synthetic
biology applications.2−5 Bacteria contain on the order of
hundreds of noncoding regulatory RNAs with the most
abundant class being the trans-encoded small RNAs
(sRNAs). sRNAs bind to mRNA targets through short,
imperfect, base-pairing interactions. This results in the
modulation of translation, and/or stability of the mRNA
target(s), by affecting ribosome binding site (RBS) accessi-
bility, or susceptibility to ribonucleases, respectively.6,7
Individual sRNAs are typically integrated into complex gene
circuits in which multiple sRNAs target multiple mRNAs to
collectively control gene expression programs using a variety of
regulatory strategies.8 For example, sRNA-controlled gene
circuits are often employed to regulate aspects of bacterial
pathogenesis.9,10 Therefore, the ability to predictably modulate
these gene circuits has potential with regard to reprogramming
gene expression for both synthetic biology and antibacterial
purposes.
Since sRNA−mRNA base-pairing interactions are the basis
of sRNA-regulated gene circuits, the obvious choice for a
synthetic modulator would be an antisense oligonucleotide
(ASO). ASOs are short, single-stranded oligonucleotides that
bind to a complementary RNA target to affect its
function.11−13 Their sequence dependence means that they
can be rationally designed to target any RNA of interest.
Targeting mRNAs with ASOs is the strategy that is typically
employed in the RNA therapeutics12 and antibacterial11,13
ASO fields. In the case of sRNA−mRNA interactions, an ASO
that targets the mRNA (an anti-mRNA ASO) would effectively
mimic the sRNA, leading to the formation of anti-mRNA
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ASO−mRNA interactions, blocking the formation of sRNA−
mRNA interactions. In contrast, an anti-sRNA ASO, that
mimics the mRNA target and sequesters the sRNA would
inhibit sRNA activity to prevent the sRNA−mRNA
interaction. Indeed, there are examples of endogenous “sponge
RNAs”14 and synthetic anti-miRNAs3 that utilize this
mechanism of target mimicry. Both strategies have merit;
however, here we have focused on expanding existing two-
component sRNA/mRNA systems to three-component
sRNA/mRNA/anti-sRNA systems.
We decided to target the sRNA−mRNA interactions that
are central to the quorum sensing system of the human
pathogen Vibrio cholerae (see Supporting Figure S1 for a
simplified schematic). V. cholerae utilizes an sRNA-regulated
gene circuit to orchestrate group behaviors, including host
colonization and virulence factor production, in response to
cell density.15−17 At low cell density, during the early stages of
infection, four functionally redundant quorum regulatory
sRNAs (Qrr1−4) are expressed.18,19 The Qrr sRNAs target a
number of mRNAs, including hapR mRNA, which encodes the
master regulator HapR.18−21 Base-pairing between the Qrr
sRNAs and the 5′ untranslated region (UTR) of hapR mRNA
is facilitated by Hfq and represses hapR.18−21 hapR repression
is one key factor that ultimately results in a gene expression
profile that promotes host colonization and virulence factor
production. Conversely, at high cell density, during the late
stages of infection, the Qrr sRNAs are no longer expressed. In
the absence of the Qrr sRNAs, hapR expression is activated,
and this promotes a gene expression profile that favors release
of the bacterium from the host, ready for the infection cycle to
begin again. Sequestering the Qrr sRNAs with an anti-Qrr
sRNA ASO, and thereby preventing Qrr sRNA−hapR mRNA
interactions, would be expected to reprogram the gene circuit,
locking it into the high cell density expression profile, which
could have antibacterial implications.
In the current work, we developed a pipeline for generating
anti-sRNA ASOs to reprogram gene expression (Figure 1) and
demonstrated its application to V. cholerae quorum sensing
sRNA−mRNA interactions. The input for the pipeline was the
V. cholerae Qrr sRNA−hapR mRNA interactions. We rationally
designed two anti-Qrr sRNA ASOs to target the Qrr sRNAs
and inhibit the Qrr sRNA−hapR mRNA interactions. These
were synthesized as peptide nucleic acids (PNAs), a synthetic
DNA mimic with a neutral backbone22 (Supporting Figure
S2A). An in vitro Qrr sRNA−hapR mRNA interaction assay,
based on our innovative RNA array technology,23 was
established to monitor the sRNA−mRNA interactions. The
anti-Qrr sRNA ASOs were screened, using this assay, for the
ability to inhibit the Qrr sRNA−hapR mRNA interactions.
Both anti-Qrr sRNA ASOs inhibited the Qrr sRNA−hapR
mRNA interactions. Finally, a Qrr1/hapR−mCherry gene
expression reporter assay was developed in Escherichia coli to
test the ability of the anti-Qrr sRNA ASOs to reprogram gene
expression in a cellular environment. One anti-Qrr sRNA ASO
Figure 1. A pipeline for the production of anti-sRNA ASOs to reprogram gene expression. The input is an sRNA−mRNA interaction of interest.
Anti-sRNA ASOs are rationally designed to target the sRNA. An in vitro sRNA−mRNA interaction assay is established. The anti-sRNA ASOs are
screened in the in vitro sRNA−mRNA interaction assay. Promising anti-sRNA ASOs are evaluated in a gene expression assay. The output anti-
sRNA ASO gene expression modulator can be taken forward for future applications, e.g., integration into synthetic gene circuits or the development
of antibacterial ASOs.
Figure 2. Rational design of anti-Qrr sRNA ASOs. (A) A multiple sequence alignment of the reverse complement of V. cholerae hapR mRNA (−80
to +10; red, hapR rc) and Qrr sRNAs (blue, Qrr1−4). The RNA sequences were extracted from Lenz et al.18 and aligned in Clustal Omega.24 The
alignment was edited manually based on Lenz et al.18 The locations of the ribosome binding site (RBS) and start codon (Start) within the hapR rc
sequence are indicated. The 32-nucleotide hapR-interacting region,18 within the Qrr sRNAs, is highlighted with a gray box. Identity between the
Qrr sRNAs and the hapR rc sequence, representing nucleotides which mediate the Qrr sRNA−hapR mRNA interactions, is indicated by asterisks.
(B) The sequences of the anti-Qrr sRNA ASOs (green, Anti-Qrr sRNA ASO A; purple, Anti-Qrr sRNA ASO B) and their target binding sites
within the hapR mRNA-interacting region of the Qrr sRNAs (blue). Asterisks indicate the expected base-pairing interactions between the anti-Qrr
sRNA ASOs and the Qrr sRNAs.
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successfully derepressed the Qrr1/hapR−mCherry reporter
system, validating it as a synthetic gene expression modulator.
Therefore, the output from the pipeline was an anti-Qrr sRNA
ASO that can inhibit Qrr sRNA−hapR mRNA interactions and
modulate gene expression. This anti-sRNA ASO has potential
for reprogramming gene expression for synthetic biology and/
or antibacterial purposes.
■ RESULTS AND DISCUSSION
Rational Design of Anti-Qrr sRNA ASOs. The first stage
of the pipeline to produce anti-sRNA ASOs to modulate gene
expression is to design anti-Qrr sRNA ASOs to target the Qrr
sRNAs and inhibit the Qrr sRNA−hapR mRNA interactions.
To do this, we needed to both identify a target site within the
Qrr sRNAs and select an appropriate chemistry for ASO
synthesis. V. cholerae contains four Qrr sRNAs (Qrr1−4)
which each contain an identical 32-nucleotide region that
interacts with the 5′ UTR of hapR mRNA to block the RBS
and inhibit translation18 (Figure 2A). Therefore, this was the
obvious region to target with anti-Qrr sRNA ASOs.
Furthermore, because this region is identical in each Qrr
sRNA, an anti-Qrr sRNA ASO targeting this region should
target all four Qrr sRNAs.
With regard to ASO chemistry, we ruled out using
unmodified DNA or RNA because early attempts to use
natural oligonucleotide ASOs had limited success due to their
susceptibility to cellular nucleases and the challenges of poor
cellular uptake.11−13 Chemical advances in the ASO field have
resulted in a number of synthetic nucleic acid analogues that
have improved resistance to nucleases, enhanced binding
specificity, and enhanced binding kinetics.12,13 Those most
commonly employed for bacterial applications include PNAs
and phosphorodiamidate morpholinos (PMOs).11,13 We
decided to use PNAs for our anti-Qrr sRNA ASOs due to
the accessibility of custom PNA synthesis. The optimal length
for PNA ASOs has been found to be 10 to 12 nucleotides.25,26
Considering this parameter, two ASO sequences, one 10
nucleotides in length and one 12 nucleotides in length, were
designed to target the core hapR-interacting region within the
Qrr sRNAs (Figure 2B). These anti-Qrr sRNA ASO sequences
were synthesized as fluorophore−cell-penetrating peptide
(CPP)−PNA conjugates (Supporting Figure S2B and C).
Development of an In Vitro Interaction Assay to
Monitor Qrr sRNA−hapR mRNA Interactions. Having
rationally designed anti-Qrr sRNA ASOs, we needed to
develop an in vitro Qrr sRNA−hapR mRNA interaction
assay in which to screen them. We recently developed an
innovative “sandwich” method for the production of func-
tional-RNA arrays, involving in vitro transcription of a DNA
template array and in situ RNA capture on a facing surface.23
These RNA arrays can be used as a platform for investigating
multiple RNA-based interactions, including sRNA−mRNA
interactions, in parallel.23,27,28 Consequently, we decided to use
this technology to generate a Qrr sRNA array, to be used as the
basis for a Qrr sRNA−hapR mRNA interaction assay (Figure
3).
To generate a Qrr sRNA array, we first needed to design in
vitro transcription DNA templates encoding the Qrr sRNAs.
Double-stranded in vitro transcription templates all had the
general architecture shown in Figure 3A.23 The Qrr sRNAs
that are transcribed from these templates will be Qrr sRNA−
linker−streptavidin-binding RNA aptamer conjugates. Briefly,
a 5′-biotinylated linker facilitates immobilization on a
streptavidin-coated surface. This is followed by a T7 promoter
and a GGG trinucleotide repeat. The GGG sequence ensures
that there is a G in the +1, +2, and +3 positions, as required for
optimal T7 RNA polymerase activity.29 Next is the sequence
encoding the Qrr sRNA (QrrX) followed by a sequence
Figure 3. Generating a Qrr sRNA array. (A) A schematic showing the general architecture of the DNA in vitro transcription templates. From 5′ to
3′ each double-stranded DNA template consists of a 5′ biotinylated linker, a T7 promoter, a GGG trinucleotide repeat, a sequence encoding the
Qrr sRNA (QrrX), a sequence encoding a linker, and a sequence encoding a streptavidin-binding RNA aptamer. In vitro transcription templates
were designed for Qrr1−4 sRNAs and a control Qrr sRNA, QrrC, which is Qrr1 with a scrambled hapR mRNA-interacting region. The sequences
of the in vitro transcription templates can be found in Supporting Table S1. (B) A schematic of the “sandwich” method,23 involving in vitro
transcription and in situ RNA capture, that was used to generate the Qrr sRNA arrays. A DNA template arrayin vitro transcription reagent
solutionstreptavidin-coated RNA capture slide “sandwich” was assembled. Qrr sRNAs were synthesized by in vitro transcription and captured in
situ on a streptavidin-coated RNA capture surface, via their streptavidin-binding RNA aptamer affinity tag. The result is an sRNA array.
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encoding a short linker sequence and, finally, a sequence
encoding a streptavidin-binding RNA aptamer. The linker aims
to promote the independent folding of the Qrr sRNA and the
streptavidin-binding RNA aptamer, and it also provides a
binding site for a fluorescently labeled DNA oligonucleotide
probe, enabling quantification of the relative levels of Qrr
sRNA on the generated array.27,28 The 3′ streptavidin-binding
RNA aptamer acts as an affinity tag to facilitate in situ surface
capture of the RNA. In vitro transcription templates were
designed for all four Qrr sRNAs (Qrr1−4) and a control Qrr
sRNA (QrrC) which is Qrr1 with a scrambled hapR mRNA-
interacting region (see Supporting Table S1 for sequences).
QrrC should not interact with hapR mRNA and should not be
targeted by the anti-Qrr sRNA ASOs.
We then set out to generate a Qrr sRNA array using our
“sandwich” method (Figure 3B).23 5′-Biotinylated in vitro
transcription templates for Qrr1−4 and QrrC were assembled
by gene synthesis and PCR. These were spotted onto a
streptavidin-coated DNA capture surface (a glass microarray
slide), in an array format, using an automated arrayer (Figure
4A, upper panel). A DNA template arrayin vitro tran-
scription reagent solutionRNA capture surface (a streptavi-
din-coated glass microarray slide) “sandwich” was then
assembled (Figure 3B). As in vitro transcription proceeded,
the Qrr sRNAs were captured in situ, via their streptavidin-
binding RNA aptamer affinity tag, as an RNA array on the
RNA capture surface (Figure 3B and Figure 4A, lower panel).
The 3′ location of the streptavidin-binding RNA aptamer
affinity tag ensured that only fully transcribed, full-length RNA
transcripts, with a correctly folded streptavidin-binding RNA
aptamer, were captured to generate the sRNA array.
Once the Qrr sRNA array had been produced, Qrr sRNA−
hapR mRNA interactions needed to be established on the
array. This required the cognate hapR mRNA. Since the known
sequence and structural elements required for the Qrr sRNAs
to bind to hapR mRNA are contained entirely within the 5′
UTR of the hapR mRNA,18−21 a minimal hapR mRNA
molecule consisting of the complete 5′ UTR and 10
nucleotides of the protein-coding region was designed to
contain these elements. We have previously shown that this
region of hapR mRNA is sufficient to facilitate the V. cholerae
Qrr1 sRNA−hapR mRNA interaction on an RNA array.23 An
in vitro transcription template encoding the hapR minimal
mRNA was designed, and this was generated by gene synthesis.
Internally, Cy5-labeled hapR minimal mRNA (Cy5-hapR
minimal mRNA) was produced by supplementing a standard
in vitro transcription reaction with Cy5-UTP. When a solution
of Cy5-hapR minimal mRNA is added to a Qrr sRNA array, it
would be expected to interact with Qrr1−4 sRNAs to establish
Qrr sRNA−hapR mRNA interactions on the array, but it
would not be expected to interact with QrrC, which lacks a
functional hapR mRNA-interacting region (Figure 4B). A
solution of Cy5-hapR minimal mRNA was added to the Qrr
sRNA array, and the array was visualized under conditions to
detect Cy5 fluorescence. Cy5 fluorescence was clearly detected
at the array positions containing Qrr1, Qrr2, Qrr3, and Qrr4
sRNAs, indicating that Cy5-hapR minimal mRNA had bound
to these sRNAs to establish Qrr sRNA−hapR mRNA
interactions (Figure 4C, upper panel). As expected, no Cy5
fluorescence could be detected at the positions containing
QrrC, suggesting that Cy5-hapR minimal mRNA does not bind
to QrrC (Figure 4C, upper panel).
As can be seen in Figure 4C, upper panel, the observed Cy5
fluorescence, representing the Qrr sRNA−hapR mRNA
interactions, was variable. This could be due to variable
amounts of Qrr sRNA being present at each position of the
Figure 4. An in vitro Qrr sRNA−hapR mRNA interaction assay. (A, upper panel) A schematic layout of a 4 × 3 field of the Qrr sRNA DNA
template array (Qrr1, Q1; Qrr2, Q2; Qrr3, Q3; Qrr4, Q4; QrrC, QC). No DNA was spotted at the positions indicated by dashed circles. (A, lower
panel) A schematic layout of a 4 × 3 field of the expected Qrr sRNA array. No RNA was expected to be captured at the positions indicated by
dashed circles. Note that the layout of the Qrr sRNA array is the mirror image of the DNA template array. (B) A schematic of Cy5-hapR minimal
mRNA applied to a Qrr sRNA array in solution. Cy5-hapR minimal mRNA is expected to bind to Qrr1−4 sRNAs to establish Qrr sRNA−hapR
mRNA interactions. Cy5-hapR minimal mRNA is not expected to bind to QrrC. The Cy5 fluorescence that would be expected to be observed on
the sRNA array is also shown schematically. (C, upper panel) A representative 4 × 3 field of a Qrr sRNA array, following the application of Cy5-
hapR minimal mRNA, visualized for Cy5 fluorescence (the array layout is as shown in A, lower panel). (C, lower panel) A bar chart of the
normalized mean Cy5 fluorescence observed for Qrr1, Qrr2, Qrr3, Qrr4, and QrrC sRNAs when Cy5-hapR minimal mRNA was applied to the Qrr
sRNA array. The Cy5 fluorescence at each array position was normalized to the Dy649 fluorescence observed at the same array position when
Dy649-RNA linker probe was applied to the same Qrr sRNA array, following a wash step to remove bound Cy5-hapR minimal mRNA (Supporting
Figure S3). The mean fluorescence intensity for each Qrr sRNA has been normalized to the highest mean fluorescence intensity (Qrr3 sRNA).
Error bars represent the standard deviation.
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Qrr sRNA array, depending upon the combined efficiency of
RNA synthesis and capture at that position. To control for
varying transcription/capture efficiencies, we decided to
determine the relative amount of Qrr sRNA present at each
array position and normalize the observed Cy5 fluorescence to
this value. To this end, we designed a 5′ Dy649-labeled single-
stranded 20-mer DNA oligonucleotide, complementary to the
common linker region between the Qrr sRNA and the
streptavidin-binding RNA aptamer (Dy649-RNA linker
probe). When a solution of Dy649-RNA linker probe is
added to a Qrr sRNA array, it would be expected to interact
with Qrr1−4 sRNA and QrrC sRNA (Supporting Figure S3A).
We have previously utilized fluorescently labeled complemen-
tary DNA oligonucleotides to probe the relative amount of
RNA present at individual positions of an RNA array.27,28
Given that the Cy5-hapR minimal mRNA and Dy649-RNA
linker probe are expected to bind to different regions of the
Qrr sRNAs, it is unlikely that binding of one would affect
binding of the other. However, Cy5-hapR minimal mRNA can
also be efficiently removed from the Qrr sRNA during a wash
step, prior to the addition of Dy649-RNA linker probe
(Supporting Figure S4A). Since similar results were obtained
with Dy649-RNA linker probe regardless of whether or not the
array had been previously exposed to Cy5-hapR minimal
mRNA (Supporting Figure S4), we elected to first expose the
Qrr sRNA array to Cy5-hapR minimal mRNA, then remove
Figure 5. Evaluating anti-Qrr sRNA ASO activity in vitro. (A) A schematic layout of a 4 × 3 field of the Qrr sRNA DNA template array and a 4 × 3
field of the Qrr sRNA array, as described in the legend to Figure 4. (B) A schematic showing the expected outcomes when a solution of either Cy5-
hapR minimal mRNA alone, or a mixture of Cy5-hapR minimal mRNA and anti-Qrr sRNA ASO, is applied to a Qrr sRNA array (see the main text
for further description). (C and D, left panels) A representative 4 × 3 field of a Qrr sRNA array, following the application of Cy5-hapR minimal
mRNA, visualized for Cy5 fluorescence (the array layout is as shown in A, lower panel). (C and D, middle panels) A representative 4 × 3 field of a
Qrr sRNA array, following the application of a mixture of Cy5-hapR minimal mRNA and anti-Qrr sRNA ASO (C, Anti-Qrr sRNA ASO A; D, Anti-
Qrr sRNA ASO B), visualized for Cy5 fluorescence (the array layout is as shown in A, lower panel). (C and D, right panels) A bar chart of the
normalized mean Cy5 fluorescence observed for Qrr1, Qrr2, Qrr3, Qrr4, and QrrC sRNAs when Cy5-hapR minimal mRNA (red bars) and a
mixture of Cy5-hapR minimal mRNA and anti-Qrr sRNA ASO (pink bars; C, Anti-Qrr sRNA ASO A; D, Anti-Qrr sRNA ASO B), was applied to
the Qrr sRNA array. The Cy5 fluorescence at each array position was normalized to the Dy649 fluorescence observed at the same array position
when Dy649-RNA linker probe was applied to the same Qrr sRNA arrays, following a wash step to remove bound Cy5-hapR minimal mRNA
(Supporting Figure S5). The mean fluorescence intensity for each Qrr sRNA has been normalized to the highest mean fluorescence intensity. Error
bars represent the standard deviation.
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the bound Cy5-hapR minimal mRNA with a wash step, and
finally probe with Dy649-RNA linker probe.
The hapR minimal mRNA-bound Qrr sRNA array (Figure
4C, upper panel) was washed, to remove the bound Cy5-hapR
minimal mRNA, probed with Dy649-RNA linker probe, and
visualized for Dy649 fluorescence (Supporting Figure S3B and
C). Dy649 fluorescence was detected at the array positions
containing Qrr1, Qrr2, Qrr3, Qrr4, and QrrC sRNAs,
indicating that Dy649-RNA linker probe had bound to all
five Qrr sRNAs and, critically, that all five Qrr sRNAs had been
efficiently synthesized and captured (Supporting Figure S3C,
upper panel). Detection of QrrC, using Dy649-RNA linker
probe, supports the conclusion that the lack of Cy5
fluorescence observed at the QrrC positions is due to the
expected lack of Cy5-hapR minimal mRNA binding, and not
due to failure of the RNA transcription/capture procedure.
The relative levels of each Qrr sRNA did vary (Supporting
Figure S3C, lower panel), indicating that the Qrr sRNAs are
synthesized/captured with different efficiencies. It is not clear
why the transcription/capture efficiencies vary, but it does
highlight the need to factor in the captured RNA levels on the
array, when analyzing data. When the Cy5 fluorescence
intensity, corresponding to bound Cy5-hapR minimal
mRNA, was normalized to the Dy649 fluorescence, to adjust
for the Qrr sRNA level, it appears that a similar fraction of
Qrr1, Qrr2, Qrr3, and Qrr4 sRNA is bound by Cy5-hapR
minimal mRNA (Figure 4C, lower panel).
Evaluation of Anti-Qrr sRNA ASO Activity In Vitro.
Having rationally designed anti-Qrr sRNA ASOs, and
established an in vitro assay to monitor the Qrr sRNA−hapR
mRNA interactions, the next step was to screen the anti-Qrr
sRNA ASOs for the ability to target the Qrr sRNAs and inhibit
the sRNA−hapR mRNA interactions. A Qrr sRNA array of
Qrr1−4 and QrrC sRNAs was generated (Figure 5A), as
described above. Parallel experiments were then performed in
which a solution of either Cy5-hapR minimal mRNA alone, or
a mixture of Cy5-hapR minimal mRNA and anti-Qrr sRNA
ASO, was applied to the Qrr sRNA array. In the absence of
anti-Qrr sRNA ASO, Cy5-hapR minimal mRNA would be
expected to bind to sRNAs Qrr1−4 (Figure 5B, left). In the
presence of anti-Qrr sRNA ASO, three outcomes are possible
(Figure 5B, right). First, Cy5-hapR minimal mRNA may
completely outcompete the anti-Qrr sRNA ASO to bind to the
Qrr sRNAs, which would result in an observed Cy5
fluorescence level similar to that observed in the absence of
anti-Qrr sRNA ASO. Second, Cy5-hapR minimal mRNA may
partially outcompete the anti-Qrr sRNA ASO such that some
Qrr sRNA molecules will be bound by Cy5-hapR minimal
mRNA and others will be bound by anti-Qrr sRNA ASO. In
this case, the observed Cy5 fluorescence would be reduced
compared to that observed in the absence of anti-Qrr sRNA
Figure 6. Evaluating anti-Qrr sRNA ASO activity in a gene expression assay. (A) A schematic representation of the hapR-mCherry, Qrr1, and QrrC
expression plasmids (see Supporting Table S3 for sequence information). hapR-mCherry is expressed from the constitutive T7A1 promoter. Qrr1
and QrrC expression is induced with IPTG using the pET system. (B and C) Bar charts showing the relative mCherry fluorescence observed in the
presence of the indicated system components. Data are the mean of three experimental repeats, and error bars represent the standard deviation.
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ASO. Finally, the anti-Qrr sRNA ASO could completely
outcompete Cy5-hapR minimal mRNA, which would result in
no Cy5 fluorescence being observed.
As observed previously (Figure 4C), when Cy5-hapR
minimal mRNA was applied to the Qrr sRNA in the absence
of anti-Qrr sRNA ASO, Cy5 fluorescence was detected at the
array positions containing Qrr1, Qrr2, Qrr3, and Qrr4 sRNAs
but not at the array positions containing the negative control
sRNA QrrC (Figure 5C and D, left panels). When a mixture of
Cy5-hapR minimal mRNA and anti-Qrr sRNA ASO was added
to the Qrr sRNA array, Cy5 fluorescence could still be
detected at the positions containing Qrr1, Qrr2, Qrr3 and Qrr4
sRNAs; however, the Cy5 fluorescence levels were much lower
than those observed in the absence of anti-Qrr sRNA ASO
(Figure 5C and D, middle panels). This effect was greater for
Anti-Qrr sRNA ASO A than it was for Anti-Qrr sRNA B. To
confirm that the reduction in Cy5 fluorescence, representing
bound Cy5-hapR minimal mRNA, was most likely due to the
anti-Qrr sRNA ASOs binding to the Qrr sRNAs and
outcompeting the Cy5-hapR minimal mRNA and not due to
variable Qrr sRNA levels on the array, the relative RNA levels
were quantified using Dy649-RNA linker probe. The hapR
minimal mRNA-bound Qrr sRNA arrays (Figure 5C and D,
left and middle panels) were washed, to remove the bound
Cy5-hapR minimal mRNA, probed with Dy649-RNA linker
probe and visualized for Dy649 fluorescence (Supporting
Figure S5). When the Cy5 fluorescence was normalized to the
Dy649 fluorescence, it is clear that the anti-Qrr sRNA ASOs
inhibit Cy-5 hapR minimal mRNA binding to the Qrr sRNAs
(Figure 5C and D, right panels). Since each of the anti-Qrr
sRNA ASOs had been synthesized as a Cy3 conjugate
(Supporting Figure S2B and C), simultaneous monitoring of
both Cy5-hapR minimal mRNA and anti-Qrr sRNA ASO
binding was possible. The same Qrr sRNA arrays shown in
Figure 5C and D, middle panels, were visualized for Cy3
fluorescence (Supporting Figure S6). Cy3 fluorescence,
representing bound anti-Qrr sRNA ASO, was detected at the
array positions containing Qrr1, Qrr2, Qrr3, and Qrr4 sRNAs
but not at the array positions containing QrrC, as expected
(Supporting Figure S6). Taken together, these data suggest
that both Anti-Qrr sRNA ASO A and Anti-Qrr sRNA ASO B
bind to Qrr1−4 sRNAs and partially outcompete Cy5-hapR
minimal mRNA to inhibit the Qrr sRNA−hapR mRNA
interactions.
Evaluation of Anti-Qrr sRNA ASO Activity in a Gene
Expression Assay. Having ascertained that the anti-Qrr
sRNA ASOs are able to bind to the Qrr sRNAs and inhibit the
Qrr sRNA−hapR mRNA interactions in vitro, we next wanted
to test if this would be translated into a change in gene
expression in a cellular environment. To do this, we elected to
design a gene expression reporter assay that could be carried
out in E. coli. E. coli has been used previously to test Qrr sRNA
activity because it is both a “lab safe” organism and it does not
possess a quorum sensing system of its own, allowing direct
effects of exogenous Qrr sRNAs to be assessed (e.g., Bardill
and Hammer30). We designed a two-plasmid reporter system
to test the effects of the anti-Qrr sRNA ASOs on Qrr1 (Figure
6A). One plasmid was a low-copy number plasmid that
expressed a hapR (−80 to +3)-mCherry transcriptional fusion
from the constitutive T7A1 promoter (pACYC177[PT7A1-
hapR-mCherry]). The second was a medium-copy number
pET plasmid that, upon induction with IPTG, expressed either
Qrr1 sRNA (pET28[PT7-Qrr1]) or the control QrrC sRNA
(pET28[PT7-QrrC]). In the absence of IPTG, hapR-mCherry
was constitutively expressed, and mCherry fluorescence was
high (Figure 6B and C, first bars). Upon addition of IPTG, the
expression of Qrr1, or QrrC, sRNA was induced. Induction of
Qrr1 sRNA resulted in repression of hapR-mCherry and a
reduction in mCherry fluorescence (Figure 6B, compare first
and second bars). This can be explained if, as expected, Qrr1
sRNA binds to hapR-mCherry mRNA, blocking the RBS, and
inhibiting translation. In contrast, induction of QrrC sRNA,
which is not expected to bind to hapR-mCherry, did not
repress hapR-mCherry or lead to a reduction in the observed
mCherry fluorescence (Figure 6C, compare first and second
bars).
We next wanted to test the effect of the anti-Qrr sRNA
ASOs on mCherry fluorescence, both in the absence of Qrr
sRNAs and in the presence of either Qrr1 sRNA or QrrC
sRNA. Cellular uptake of “naked” PNA by E. coli is known to
be inefficient.11−13 This can be improved by conjugating the
PNA to a cell-penetrating peptide (CPP).13 Good et al. have
demonstrated that uptake of PNAs by E. coli can be facilitated
through the conjugation of the CPP (KFF)3K to the PNA.
25 It
was for this reason that our anti-Qrr sRNA ASOs were
synthesized with this CPP conjugated to the PNA ASO
(Supporting Figure S2B and C). In the absence of Qrr sRNAs,
neither anti-Qrr sRNA ASO affected mCherry fluorescence
(Figure 6B and C, compare first, third, and fourth bars). In the
presence of both Qrr1 sRNA and Anti-Qrr sRNA ASO A, the
observed mCherry fluorescence was similar to that observed in
the presence of Qrr1 sRNA alone (Figure 6B, compare second
and fifth bars). However, in the presence of both Qrr1 and
Anti-Qrr sRNA ASO B, hapR-mChery was derepressed and the
observed mCherry fluorescence was restored to that observed
in the absence of Qrr1 (Figure 6B, compare first and sixth
bars). In the presence of QrrC, which does not repress hapR-
mCherry and affect mCherry fluorescence, addition of anti-Qrr
sRNA ASO also did not affect mCherry fluorescence (Figure
6C, compare, first, second, fifth, and sixth bars). These results
suggest that Anti-Qrr sRNA ASO B successfully targets Qrr1
sRNA to modulate hapR-mCherry expression in a cellular
environment.
The lack of activity of Anti-Qrr sRNA ASO A in the gene
expression assay was surprising given the results from the in
vitro interaction assay (Figure 5). There are several possibilities
for this result, including an insufficient intracellular concen-
tration of Anti-Qrr sRNA ASO A to outcompete hapR-
mCherry mRNA for Qrr1 binding. This could be due to poor
cellular uptake and/or sequestration of Anti-Qrr sRNA ASO A.
We had attempted to mitigate the risk of poor cellular uptake
by conjugating the anti-Qrr sRNA ASOs to a CPP (Supporting
Figure S2B and C), and this strategy appears to have been
successful for Anti-Qrr sRNA ASO B. Since the anti-Qrr sRNA
ASOs were Cy3-labeled, we used confocal microscopy to
visualize the mCherry and Cy3 fluorescence in E. coli cells
expressing hapR-mCherry in the presence of Anti-Qrr sRNA
ASO A (Supporting Figure S7). The fluorescence from
mCherry did appear to coincide with the Cy3 fluorescence
from Anti-Qrr sRNA ASO A, indicating that the anti-Qrr
sRNA ASO is entering the cells. As E. coli does take up Anti-
Qrr sRNA ASO A, a possibility is that it is sequestered by
binding to an endogenous RNA. Off-target effects are known
to be a common problem with ASOs, in part due to their
relatively short length failing to provide the required specificity
in a cellular context.12,26 The specificity of the longer 12-
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nucleotide Anti-Qrr sRNA ASO B may be enhanced relative to
10-nucleotide Anti-Qrr ASO A.
An Anti-Qrr sRNA ASO Inhibitor of Qrr sRNA−hapR
mRNA Binding Interactions Which Modulates Gene
Expression. We have successfully developed a pipeline for the
production of anti-sRNA ASOs and used it to produce an anti-
Qrr sRNA ASO (Anti-Qrr sRNA ASO B) that both inhibits
Qrr sRNA−hapR minimal mRNA binding interactions in vitro
and modulates gene expression in a Qrr1 sRNA/hapR-
mCherry reporter system, in E. coli. This effectively expands
an existing two-component gene expression system to a three-
component gene expression system. Although we have focused
on the individual Qrr sRNA−hapR mRNA interactions, this
could be expanded further to incorporate all four Qrr sRNAs,
hapR mRNA, and Anti-Qrr sRNA ASO B. Likewise, although
we evaluated gene expression using a reporter system in E. coli,
it is anticipated that this would be readily transferrable to cell-
free expression systems.
The Qrr sRNA−hapR mRNA interactions are central to the
quorum sensing system that coordinates the infection cycle of
V. cholerae15−17 (Supporting Figure S1). The Qrr sRNA−hapR
mRNA interactions are required during the early stages of V.
cholerae infection to establish a gene expression profile which
promotes virulence (Supporting Figure S1). However, the lack
of Qrr sRNA expression at the late stages of infection results in
the absence of Qrr sRNA−hapR mRNA interactions and
promotes release of V. cholerae from its host (Supporting
Figure S1). Due to the link between quorum sensing systems
and pathogenesis, quorum sensing has been identified as a
process with potential for antibacterial targeting.31,32 Inhibition
of the Qrr sRNA−hapR mRNA interactions, by Anti-Qrr
sRNA ASO B, would be expected to effectively mimic the
situation at high cell density when there are no Qrr sRNAs
present, and this might be expected to prevent host
colonization and virulence factor production. Therefore,
Anti-Qrr sRNA ASO B also has potential as a lead compound
for antibacterial targeting of V. cholerae through the
reprogramming of gene expression.
A Pipeline for Targeting RNA-Based Interactions to
Modulate Gene Expression. Although we have applied our
pipeline to a very specific bacterial RNA-based interaction,
there is enormous scope to expand its applicability (Figure 7).
The input for the pipeline can be essentially any regulatory
RNA-based interaction involved in gene expression, including
RNA−RNA interactions, RNA−protein interactions, and
RNA−small molecule interactions. These interactions may be
targeted for synthetic biology, antimicrobial, and/or therapeu-
tic purposes. For example, target RNA−RNA interactions
could be bacterial sRNA−mRNA interactions, such as the Qrr
sRNA−hapR interactions, or the analogous eukaryotic micro
RNA (miRNA)−mRNA interactions.33 Increasing numbers of
miRNAs are being identified as attractive therapeutic targets
due to their role(s) in human diseases such as cancer,
cardiovascular disease, and diabetes.3 Or, it may be desirable to
target the RNA−protein interactions involved in the tran-
scription and translation processes or the RNA−small
molecule interactions central to the action of bacterial
riboswitches.34
The first stage of the pipeline is to select candidate inhibitors
to target the RNA-based interaction. Candidate inhibitors can
be rationally designed, or could be screening libraries. For
RNA−RNA interactions, assuming that the sequence of the
RNA-binding partners is known, it is relatively straightforward
to rationally design ASOs to target the interacting region of
one, or both, of the RNAs. As we have demonstrated here for
the Qrr sRNAs and hapR mRNA, this approach may only
require the design of a handful of candidate ASO inhibitors.
ASOs could also be designed to target known protein-binding,
or small molecule-binding, sites within an RNA, although this
information is often less readily available. Alternatively, there is
precedent for targeting RNA with small molecules, e.g.,
riboswitches34 and antimicrobial aminoglycosides that target
16S rRNA.35 The rational design of small molecule inhibitors
is far more challenging than ASO design and often, a screening
library of hundreds, or thousands, of small molecules is likely
to be a suitable starting point in this case. Having selected
candidate inhibitors, the next step of the pipeline is to establish
Figure 7. A pipeline for the production of modulators of gene expression. The input for the pipeline is a regulatory RNA-based interaction involved
in gene expression. Candidate inhibitors, which could be ASOs or small molecules, are rationally designed, or selected for screening, to target the
RNA-based interaction. A simple in vitro binding assay, using functional-RNA array technology,23 is then established. This can be extended to
monitor the gene expression output on a reporter-protein array.27 Candidate inhibitors are screened using the simple in vitro assay(s). Their ability
to modulate gene expression is validated in a cellular environment. The outputs from the pipeline are gene expression modulators that can be taken
forward in the development of synthetic biology, antibacterial, or therapeutic strategies.
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a simple in vitro assay, to monitor the RNA-based interaction,
that can be used for inhibitor screening. Regardless of whether
the input is an RNA−RNA, RNA−protein, or RNA−small
molecule interaction, a simple binding assay can be used to
monitor the interaction. We elected to use functional-RNA
arrays23 as the basis for the RNA−RNA Qrr sRNA−hapR
mRNA binding interactions. Although other interaction
methodologies could be employed, e.g., surface plasmon
resonance (SPR)36 or electrophoretic mobility shift assays
(EMSAs), an advantage of using RNA array technology is its
high-throughput capacity. This capacity can be used to
perform multiple experimental repeats in parallel on a single
RNA array, for a small number of related interactions, as we
have done here for the four Qrr sRNA−hapR mRNA
interactions. Alternatively, it can be used to monitor multiple
orthogonal RNA-based interactions simultaneously,23 limited
only by the availability of orthogonal detection methods.
Furthermore, although a binding assay would be expected to
be predictive of the gene expression outcome, this can be
directly assessed by taking the RNA array-based binding assay
and using it, in turn, to generate a reporter-protein array.27
This provides a cell-free gene expression readout. Having
established a suitable in vitro assay, the candidate inhibitors are
then screened in order to identify inhibitors with potential to
modulate gene expression. Both of the anti-Qrr sRNA ASOs
that we had rationally designed inhibited the Qrr sRNA−hapR
mRNA interactions in a binding assay and were taken forward
for testing in a more complex assay. More complex assays are
likely to validate modulation of gene expression in a cellular
environment, which may encounter the possible challenges of
cellular uptake and/or off-target effects. Our results highlight
the importance of including this validation step since only
Anti-Qrr sRNA ASO B modulated the expression of a hapR-
mCherry reporter in a three-component Qrr1 sRNA/hapR-
mCherry mRNA/Anti-Qrr sRNA ASO B system. The output
from the pipeline is a modulator of gene expression that targets
an RNA-based interaction. This could be deployed as a switch
in a synthetic biology context. For example, the Qrr1 sRNA/
hapR-mCherry mRNA/Anti-Qrr sRNA ASO B system could
be integrated into synthetic gene circuits, or adapted to control
other pathways. Alternatively, if the RNA-based interactions
are of interest from an antibacterial or therapeutic perspective,
as is the case for the Qrr sRNA−hapR mRNA interactions, the
inhibitor/modulator could be taken forward as a lead
compound in an antibacterial or therapeutic strategy.
■ CONCLUDING REMARKS
In conclusion, we have developed a pipeline to produce
inhibitors of regulatory RNA-based interactions which can be
used as modulators of gene expression. We designed two anti-
Qrr sRNA ASOs to target the V. cholerae Qrr sRNAs, inhibit
the Qrr sRNA−hapR mRNA interactions, and thereby regulate
hapR expression. A simple RNA array-based Qrr sRNA−hapR
mRNA interaction assay was designed to screen the anti-Qrr
sRNA ASOs for the ability to inhibit the Qrr sRNA−hapR
mRNA interaction, demonstrating the potential to modulate
gene expression of a two component Qrr sRNA/hapR mRNA
system. Both anti-Qrr sRNA ASOs were able to outcompete
hapR mRNA in this interaction assay. We went on to show that
one of the anti-Qrr sRNA ASOs (Anti-Qrr sRNA ASO B)
derepresses a Qrr sRNA/hapR mRNA reporter system in a
cellular environment. We anticipate that this gene expression
modulator will be of use as a synthetic biology component
and/or a lead molecule for antibacterial targeting of V. cholerae.
Furthermore, we hope that the broader pipeline will find
widespread use in the identification of inhibitors of RNA-based
interactions to reprogram gene expression for synthetic
biology, antimicrobial, and/or therapeutic applications.
■ METHODS
Anti-Qrr sRNA ASO Design and Synthesis. Anti-sRNA
ASO sequences were designed to target the Qrr sRNAs using
the PNA design tool PNABio and the default restraints (Anti-
Qrr sRNA ASO A: 5′-caa cgt cag t-3′; Anti-Qrr sRNA ASO B:
5′-tca gtt gc tag-3′). The anti-Qrr sRNA ASOs were
synthesized as Cy3−CPP−PNA conjugates (see Supporting
Figure S2B and C) by Panagene.
Production of Qrr sRNA Arrays. Design and Prepara-
tion of In Vitro Transcription Templates for DNA Template
Arrays. Double-stranded DNA in vitro transcription templates
encoding Qrr sRNA−linker−streptavidin-binding RNA ap-
tamer conjugates were designed essentially as described in
Phillips et al.23 (see Figure 3A and Results and Discussion for
details). Their sequences are presented in Supporting Table
S1. Core templates, lacking the 5′-biotinylated linker, were
initially assembled by gene synthesis (see Supporting Table S2
for the primer sequences). These were amplified in a standard
PCR reaction using the forward primer 5′-biotin-ctc gag taa tac
gac tca cta tag g-3′ and the relevant antisense 2 primer from
Supporting Table S2 as the reverse primer. The resulting
biotinylated double-stranded DNA in vitro templates were
purified using a NucleoSpin gel and PCR cleanup kit
(Macherey-Nagel). Their concentrations were determined by
measuring the A260, and their size was confirmed by agarose gel
electrophoresis.
Preparation of Streptavidin-Coated DNA and RNA
Capture Surfaces. Streptavidin-coated surfaces were prepared
as described in Phillips et al.23 Briefly, NHS-activated
Nexterion H microarray slides (Schott) were coated with 90
μL 1 μM or 90 μL 16.7 μM streptavidin in phosphate-buffered
saline (PBS) at pH 7.4, for the preparation of DNA or RNA
capture surfaces, respectively. Coated slides were covered with
a 24 × 60 mm LifterSlip (Thermo Fisher Scientific) and
incubated at 37 °C for 1 h in a humidified chamber. The
LifterSlips were removed, and the slides were washed at room
temperature with 45 mL of PBS and 0.05% (v/v) Tween 20
(PBS-T) for 5 min with rolling, followed by 45 mL of PBS for
5 min with rolling, followed by 45 mL of H2O for 5 min with
rolling (wash-cycle A). To block any unreacted NHS
functional groups, the slides were then submerged in 45 mL
of 50 mM ethanolamine-HCl at pH 8.5 and incubated at room
temperature for 30 min with rolling. The slides were washed at
room temperature following wash-cycle A and then dried by
centrifugation at 500g for 3 min at room temperature.
Preparation of DNA Template Arrays. A solution of each
5′-biotinylated in vitro transcription template was prepared at a
concentration of 300 nM in PBS. These solutions were spotted
onto a streptavidin-coated DNA capture surface in 4 × 3 fields,
at a spot separation of 2500 μm, using an automated arrayer
(Genetix Qarray2) fitted with a 200 μm pin head. Following
spotting, the slides were incubated at 20 °C and 50% relative
humidity for 30 min, washed at room temperature following
wash-cycle A, and dried by centrifugation at 500g for 3 min at
room temperature.
RNA Synthesis and In Situ Surface Capture. A DNA
template arrayin vitro transcription reagent solution (150 μL
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1× Reaction Buffer (MEGAscript T7 Transcription Kit,
Thermo Fisher Scientific), 1× Enzyme Mix (MEGAscript T7
Transcription Kit), and 0.5 mM of ATP, CTP, GTP, and
UTP)streptavidin-coated RNA capture surface “sandwich”
was assembled, essentially as described in Phillips et al.23 The
sandwich assembly was incubated at 37 °C for 90 min in a
humidified chamber to allow for in vitro transcription and in
situ RNA capture. The DNA template array and the newly
generated sRNA array were separated. The sRNA array was
washed at room temperature following wash-cycle A and dried
by centrifugation at 500g for 3 min at room temperature.
An In Vitro Qrr sRNA−hapR mRNA Interaction Assay.
Design and Synthesis of hapR Minimal mRNA. A double-
stranded DNA in vitro transcription template encoding hapR
minimal mRNA (−80 to +10) was designed to contain all of
the known sequence and structural elements required to bind
the Qrr sRNAs18−21 (see Supporting Table S1 for the
sequence). RNA secondary structure predictions were utilized
to guide the design process.37−39 The double-stranded DNA in
vitro transcription template was assembled by gene synthesis
(see Supporting Table S2 for the primer sequences). It was
purified using a NucleoSpin gel and PCR cleanup kit. Its
concentration was determined by measuring the A260, and its
size was confirmed by agarose gel electrophoresis. Cy5-labeled
hapR minimal mRNA was then synthesized by in vitro
transcription using a MEGAscript T7 transcription kit
(Thermo Fisher Scientific) supplemented with 0.05 mM
Cy5-UTP (GE Healthcare Life Sciences). Cy5-hapR minimal
mRNA was purified using a MEGAclear transcription cleanup
kit (Thermo Fisher Scientific). The concentration was
determined by measuring the A260, and its size was confirmed
by denaturing 7 M urea 10% polyacrylamide gel electro-
phoresis.
Hybridization of Cy5-hapR Minimal mRNA to Qrr sRNA
Arrays. A 1 μM solution of Cy5-hapR minimal mRNA, or a
mixture of 1 μM Cy5-hapR minimal mRNA and 1.5 μM anti-
Qrr sRNA ASO, was prepared in hybridization buffer (40 mM
Tris, pH 7.8; 6 mM MgCl2; 20 mM NaCl), heated at 80 °C for
10 min and allowed to cool at room temperature for 10 min. A
volume of 20 μL was then pipetted onto a Qrr sRNA array and
covered with a 22 × 22 mm LifterSlip (CNTech). This
assembly was incubated at 25 °C for 90 min in the dark. The
LifterSlip was removed, and the Cy5-hapR minimal mRNA-
bound Qrr sRNA array was washed at room temperature with
45 mL of hybridization buffer for 1 min with rolling, followed
by 45 mL of H2O for 10 s with rolling (wash-cycle B). The
Cy5-hapR minimal mRNA-bound Qrr sRNA array was dried
by centrifugation at 500g for 3 min at room temperature.
Visualization and Quantification of Cy5 Fluorescence.
Cy5-hapR minimal mRNA, bound to a Qrr sRNA array, was
visualized using a GenePix 4200A microarray slide scanner
(Molecular Devices) with the following settings: excitation
wavelength, 635 nm; power, 80; emission filter, Standard Red
(676/29 nm); PMT gain, 550. The fluorescence intensity at
each position of the array was quantified using GenePix
software (Molecular Devices). To aid visualization, the images
were false-colored red, and the brightness and contrast of the
images were both set to 98 in the GenePix software. Brightness
and contrast were further adjusted to 65 and 30, respectively,
in PowerPoint.
Removal of Bound Cy5-hapR Minimal mRNA from Qrr
sRNA Arrays. To remove bound Cy5-hapR minimal mRNA
from Qrr sRNA arrays, 90 μL of 2× saline-sodium citrate
(SSC) supplemented with 0.1% sodium dodecyl sulfate (SDS;
w/v) was pipetted over a Qrr sRNA array and covered with a
24 × 60 mm LifterSlip. This assembly was incubated at room
temperature for 30 min. The LifterSlip was removed, and the
Qrr sRNA array was washed at room temperature with 45 mL
of PBS-T for 5 min with rolling, followed by 45 mL of H2O for
1 min with rolling, followed by a dip in 45 mL of H2O (wash-
cycle C). The Qrr sRNA array was dried by centrifugation at
500g for 3 min at room temperature.
Dy649-RNA Linker Probe Synthesis. A Dy649-labeled DNA
oligonucleotide (5′-Dy649−gtg tgt gtg tgt gtg tgt gt-3′)
complementary to the linker region between the Qrr sRNA
and the streptavidin-binding RNA aptamer (Dy649-RNA
linker probe) was obtained from Thermo Fisher Scientific.
Hybridization of Dy649-RNA Linker Probe to Qrr sRNA
Arrays. A 100 nM solution of Dy649-RNA linker probe was
prepared in 2× SSC supplemented with 0.1% SDS. A total of
90 μL was then pipetted onto a Qrr sRNA array and covered
with a 24 × 60 mm LifterSlip. This assembly was incubated at
25 °C for 30 min in the dark. The LifterSlip was removed, and
Dy649-RNA linker probe-bound Qrr sRNA array was washed
at room temperature with 45 mL of PBS-T for 5 min with
rolling, followed by 45 mL of H2O for 1 min with rolling,
followed by a dip in 45 mL of H2O (wash-cycle D). The
Dy649-RNA linker probe-bound Qrr sRNA array was dried by
centrifugation at 500g for 3 min at room temperature.
Visualization and Quantification of Dy649 Fluorescence.
Dy649-RNA linker probe, bound to a Qrr sRNA array, was
visualized using a GenePix 4200A microarray slide scanner
with the following settings: excitation wavelength, 635 nm;
power, 80; emission filter, Standard Red (676/29 nm); PMT
gain, 550. The fluorescence intensity at each position of the
array was quantified using GenePix software. To aid visual-
ization, the images were false-colored yellow, and the
brightness and contrast of the images were both set to 98 in
the GenePix software. Brightness and contrast were further
adjusted to 65 and 30, respectively, in PowerPoint.
A Qrr/hapR-mCherry Gene Expression Assay. Gen-
eration of the hapR-mCherry, Qrr1, and QrrC Expression
Strains. DNA sequence encoding PT7A1-hapR-mCherry was
synthesized and cloned into the NheI and HindIII restriction
sites of the pACYC177 (AmpR) vector by GeneArt (Thermo
Fisher Scientific; see Supporting Table S3 for sequence
information). DNA sequences encoding PT7-Qrr1 and PT7-
QrrC were assembled by gene synthesis and cloned into the
BglII and XhoI sites of pET28b (KanR; see Supporting Table
S3 for sequence information). The sequences of the vectors
were confirmed by DNA sequencing. The E. coli expression
strain BL21(DE3) was cotransformed with pACYC177[PT7A1-
hapR-mCherry] and either pET28[PT7-Qrr1] or pET28[PT7-
QrrC].
Qrr/hapR-mCherry Gene Expression Assay. BL21(DE3)
pACYC177[PT7A1-hapR-mCherry] pET28[PT7-Qrr1] and
BL21(DE3) pACYC177[PT7A1-hapR-mCherry] pET28[PT7-
QrrC] were grown to single colonies on LB agar,
supplemented with 100 μg/mL ampicillin and 50 μg/mL
kanamycin, at 37 °C; 5 μL of resuspended cells was used to
inoculate 125 μL of Mueller-Hinton (MH) broth, supple-
mented with 100 μg/mL of ampicillin, 50 μg/mL of
kanamycin, 1% (w/v) glucose, either 0 or 200 μM IPTG,
and either 0 or 3 μM Anti-Qrr sRNA ASO A or 0 or 1.5 μM
Anti-Qrr sRNA ASO B. These cultures were incubated in black
clear-bottomed 96-well plates (Corning), with orbital shaking,
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at 37 °C, in a Hidex Sense plate reader. The OD600 and the
mCherry fluorescence (excitation wavelength, 575 nm;
emission wavelength, 616 nm) were recorded every 10 min
for 3 h. The (fluorescenceOD(600)=0.6 − fluorescen-
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